In summary, we describe transcriptomic correlates present in breast tumors with high expression of Tregs, identifying a gene signature that predicts clinical benefit of the approved check-point inhibitors PD (L)1 and CTLA4 antibodies. The gene discussed is CTLA4; the disease is breast neoplasm.